Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Nanoscale artificial antigen presenting cells for T cell immunotherapy.

Perica K, De León Medero A, Durai M, Chiu YL, Bieler JG, Sibener L, Niemöller M, Assenmacher M, Richter A, Edidin M, Oelke M, Schneck J.

Nanomedicine. 2014 Jan;10(1):119-29. doi: 10.1016/j.nano.2013.06.015. Epub 2013 Jul 24.

2.

In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC).

Durai M, Krueger C, Ye Z, Cheng L, Mackensen A, Oelke M, Schneck JP.

Cancer Immunol Immunother. 2009 Feb;58(2):209-20. doi: 10.1007/s00262-008-0542-1. Epub 2008 Jun 18.

3.

Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy.

Perica K, Bieler JG, Schütz C, Varela JC, Douglass J, Skora A, Chiu YL, Oelke M, Kinzler K, Zhou S, Vogelstein B, Schneck JP.

ACS Nano. 2015 Jul 28;9(7):6861-71. doi: 10.1021/acsnano.5b02829. Epub 2015 Jul 14.

4.

Artificial antigen-presenting cells plus IL-15 and IL-21 efficiently induce melanoma-specific cytotoxic CD8+ CD28+ T lymphocyte responses.

Yu X, He J, Mongkhoune S, Peng Y, Xie Y, Su J, Zhou SF, Xie XX, Luo GR, Fang Y, Li X, Li X, Zhou N, Zhao YX, Lu XL.

Asian Pac J Trop Med. 2013 Jun;6(6):467-72. doi: 10.1016/S1995-7645(13)60076-0.

5.

In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer.

Ugel S, Zoso A, De Santo C, Li Y, Marigo I, Zanovello P, Scarselli E, Cipriani B, Oelke M, Schneck JP, Bronte V.

Cancer Res. 2009 Dec 15;69(24):9376-84. doi: 10.1158/0008-5472.CAN-09-0400.

6.

Paracrine release of IL-2 and anti-CTLA-4 enhances the ability of artificial polymer antigen-presenting cells to expand antigen-specific T cells and inhibit tumor growth in a mouse model.

Zhang L, Wang L, Shahzad KA, Xu T, Wan X, Pei W, Shen C.

Cancer Immunol Immunother. 2017 Sep;66(9):1229-1241. doi: 10.1007/s00262-017-2016-9. Epub 2017 May 13.

PMID:
28501941
7.

Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell.

Butler MO, Lee JS, Ansén S, Neuberg D, Hodi FS, Murray AP, Drury L, Berezovskaya A, Mulligan RC, Nadler LM, Hirano N.

Clin Cancer Res. 2007 Mar 15;13(6):1857-67.

8.

A novel system of artificial antigen-presenting cells efficiently stimulates Flu peptide-specific cytotoxic T cells in vitro.

Han H, Peng JR, Chen PC, Gong L, Qiao SS, Wang WZ, Cui ZQ, Yu X, Wei YH, Leng XS.

Biochem Biophys Res Commun. 2011 Aug 5;411(3):530-5. doi: 10.1016/j.bbrc.2011.06.164. Epub 2011 Jul 2.

PMID:
21756876
9.

Adoptive transfer of pTRP2-specific CTLs expanding by bead-based artificial antigen-presenting cells mediates anti-melanoma response.

Lu X, Jiang X, Liu R, Zhao H, Liang Z.

Cancer Lett. 2008 Nov 18;271(1):129-39. doi: 10.1016/j.canlet.2008.05.049. Epub 2008 Jul 14.

PMID:
18621475
10.

Linking form to function: Biophysical aspects of artificial antigen presenting cell design.

Perica K, Kosmides AK, Schneck JP.

Biochim Biophys Acta. 2015 Apr;1853(4):781-90. doi: 10.1016/j.bbamcr.2014.09.001. Epub 2014 Sep 6. Review.

12.

Latex bead-based artificial antigen-presenting cells induce tumor-specific CTL responses in the native T-cell repertoires and inhibit tumor growth.

Shen C, Cheng K, Miao S, Wang W, He Y, Meng F, Zhang J.

Immunol Lett. 2013 Feb;150(1-2):1-11. doi: 10.1016/j.imlet.2013.01.003. Epub 2013 Jan 14.

PMID:
23328744
13.

Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells.

Oelke M, Maus MV, Didiano D, June CH, Mackensen A, Schneck JP.

Nat Med. 2003 May;9(5):619-24. Epub 2003 Apr 21.

PMID:
12704385
14.

Magnetic field-induced T cell receptor clustering by nanoparticles enhances T cell activation and stimulates antitumor activity.

Perica K, Tu A, Richter A, Bieler JG, Edidin M, Schneck JP.

ACS Nano. 2014 Mar 25;8(3):2252-60. doi: 10.1021/nn405520d. Epub 2014 Feb 24.

15.

CD47 Enhances In Vivo Functionality of Artificial Antigen-Presenting Cells.

Bruns H, Bessell C, Varela JC, Haupt C, Fang J, Pasemann S, Mackensen A, Oelke M, Schneck JP, Schütz C.

Clin Cancer Res. 2015 May 1;21(9):2075-83. doi: 10.1158/1078-0432.CCR-14-2696. Epub 2015 Jan 15.

16.

Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes.

Ye Q, Loisiou M, Levine BL, Suhoski MM, Riley JL, June CH, Coukos G, Powell DJ Jr.

J Transl Med. 2011 Aug 9;9:131. doi: 10.1186/1479-5876-9-131.

17.

HLA-Ig based artificial antigen presenting cells for efficient ex vivo expansion of human CTL.

Chiu YL, Schneck JP, Oelke M.

J Vis Exp. 2011 Apr 11;(50). pii: 2801. doi: 10.3791/2801.

18.

Peptide-beta2-microglobulin-major histocompatibility complex expressing cells are potent antigen-presenting cells that can generate specific T cells.

Obermann S, Petrykowska S, Manns MP, Korangy F, Greten TF.

Immunology. 2007 Sep;122(1):90-7. Epub 2007 Apr 30.

19.

Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis.

Xu Z, Ramishetti S, Tseng YC, Guo S, Wang Y, Huang L.

J Control Release. 2013 Nov 28;172(1):259-65. doi: 10.1016/j.jconrel.2013.08.021. Epub 2013 Sep 1.

PMID:
24004885
20.

Supplemental Content

Support Center